· METHODS:Aninterventional,restrospectivestudyof 41eyesof41patientswhohadcompleted12moof follow-up,dividedintogroup1(1.25mgofbevacizumab, 21eyesof21patients)andgroup2 (2.5mgof bevacizumab, 20 eyes of 21 patients). Complete ophthalmic examination, fluorescein angiography, enhanceddepthimagingopticalcoherencetomography andmeasurementofretinalvesseldiameterwithIVAN softwarewereperformedatbaselineandfollow-up.
· RESULTS:TheSFChTchangedfrom279.1(165-431) 滋m atbaselineto277.0(149-413) 滋mat12moingroup1( = 0.086),andfrom301.4(212-483) 滋mto300. 3(199-514) [1] [2] . Vascularendothelialgrowthfactor(VEGF)playsamainrole inbreakdownoftheblood-retinalbarrier,increasingvascular permeabilityanddevelopingmacularedema [3] [4] .Thereforethe anti-VEGFagents,whichbindandinhibitVEGF,seemtobe apromisingtherapeuticmodalityinmacularedema.Alsoin BRVO,retinalischemiaisoneofthemostimportant upregulatorsofVEGF,whichcontributetothedevelopment ofmacularedema [1] [2] [5] [6] [7] [8] . VEGFisknowntoinducevesseldilatationandhence increasesocularbloodflow amechanisminvolvingnitric oxide [9] .Alsoanti-VEGFagentsareknowntoaffectthe retinalvasculatureafterintravitrealinjection.Previous studieshavenotedchangesofretinalvascularcaliber, followingintravitrealanti-VEGFinjection [10] [11] [12] . Spaide [13] usedspectraldomain-opticalcoherence tomography (SD-OCT)anddevelopedamethodtermed enhanceddepthimaging (EDI),whichenables measurementofthethicknessofchoroid.Somereportsnoted changesinsubfovealchoroidalthickness(SFChT)after treatment,andespecially,changesofitafterintravitreal bevacizumab,wereappreciatedaspredictivefactor [14] [15] . TheaimofthisstudyistoinvestigatehowSFChTchanges andhowretinalvesselcaliberchangesaftertwodifferent dosesofintravitrealbevacizumabandcomparethechanges incentralmacularthickness(CMT)andbest-correctedvisual acuity (BCVA)afterinjectingtwodifferentdoses.Along withseveralreportsthathavedemostratedefficacyof intravitrealbevacizumabatdosesof1to2.5mgcausesan improvementinCMTandBCVA,wealsoinvestigated SFChTandretinalvascularcaliberchanges,aswellasCMT andBCVA [5] [6] . [5] [6] [7] [8] .Amongthe anti-VEGFagents,bevacizumabiswidelyusedforeconomic reasons,although,itiscurrentlyoff-labelinophthalmology. Howevertheoptimumtiming,dosingandsequenceof intravitrealbevacizumabinBRVOarestillundetermined. ThePanAmericanCollaborativeRetinaStudy(PACORES) Groupreportedthat,intravitrealbevacizumabatdosesupto 2.5mgseemstobeeffectiveinimprovingBCVAand reducingCMTinmacularedemasecondarytoBRVOinthe shortterm.However,theyreportedthatnumberofinjections, CMT,changeinBCVAarenotsignificantlydifferent betweentwodifferentdosesofintravitrealbevacizumabin long-termfollow-up(1.25mg 2.5mg) [18] [19] .Alsointhis study,numberofinjections,BCVAandCMTatlast follow-updidnotshowstatisticallysignificantdifferences betweenthetwodosegroups.Both1.25mgand2.5mg seemedtohavesimilartreatmentefficacy.Itisnotclear whetherahigherdose(2.5mg)canprovidebetteroutcomes, alongerdisease-freeintervalorreducetheburdenofmore frequentinjectionsthanalowerdose(1.25mg).Although bothdoseswerenotassociatedwithanyadverseeventsin thisstudy,the2.5mgdoseisreportedtocauseinflammatory reactioninthevitreous,andacuteposteriorvitreous detachmentwithperipheralretinalhemorrhage [20] .Unless datatosupportimprovedefficacyandsecuresafetyforthe 2.5mgdosebecomesavailable,theauthorsfavorthelower dose. Bevacizumabisknowntoaffecttheretinalandchoroidal circulationafterintravitrealinjection.Somestudieshave reportedchangesofretinalvascularcaliberafterintravitreal bevacizumabinjection.Sacu [21] reportedvasoconstriction inretinalvessels,andsignificantreductioninflowvelocities intheretrobulbarcentralretinalartery,afterthreeintravitreal injectionsofranibizumabineyeswithBRVO.Inthisstudy, afterintravitrealbevacizumabinjectioninpatientswith BRVO,changesofretinalarteriolardiameterdidnotreach statisticalsignificance.Howeversignificantvasoconstriction intheretinalvenuleswasnoted,regardlessofdosesof 
Figure5ChangeinCRVEfrombaselineto12mo
The repeated-measureANOVArevealedthattheCRVEsignificantly decreasedfrombaselinemeasurementtopost-injectiontimesinboth groups ( =0.019).And,therepeated-measureANOVArevealedno statisticallysignificantintergroupdifference( =0.834).
ChoroidalthicknessandretinalvesseldiameterinBRVO
intravitrealbevacizumab.AsPapadopoulou [10] noted, thismaybeinterpretedthatdecreaseinretinalvenular diameterreflectsareturntothenormaldiameterfroma previouslyvasodilatedstate.ItisknownthatVEGFhas effectsinvesseldiameteranditsdown-regulationsecondary tobevacizumabisexpectedtoinducevesselconstriction [22] [23] . Inonestudyofnonhumanprimates,VEGFinducedcapillary endothelialcellproliferationwithinveins, leadingto intussusceptionsandendothelialcellwallbridgingwithin venules [24] . [25] .After intravitrealinjection,bevacizumabisdeliveredtochoroid passingthroughretina,andisaccumulatedinthevascular wallofchoroid [26] .Thus,inhibitionofVEGF,byintravitreal injectionofanti-VEGFagentsmayaffectthepermeabilityof choroidalvasculatureandchoroidalthickness.Tsuiki [27] [22] .Thismaybe relatedwithshortdurationofdrugactionofbevacizumab,in pharmacokineticaspect.Consideringthat,thevitreous half-lifeisabout9.8d [28] ,andsignificantVEGFbinding activitylastsfor4wkto5wk [29] ,afterasingleintravitreal bevacizumabinjection,mostpatientsneedmorethan2 reinjections.Actuallyinthisstudy,39eyesoftotal41eyes (95%)neededreinjectionofbevacizumabwithin6moafter initialintravitrealbevacizumabinjection.Andthemeantime ofreinjectionwas2.4mo.Thisissimilartothereportof otherstudy,revealingthatmacularedemasecondaryto BRVOrelapsesinaverage2.1mo [2] . ThefinalSFChTdidnotshowstatisticallysignificant differencesfromthebaselineinbothgroups.AsVEGFlevel muchdecreasedatlastfollow-upfromthebaseline,itmight haveleasteffectsonchoroidalthickness.AsVEGFlevelis knowntoberelatedwithmacularedemaandretinal ischemia,VEGFlevelismuchdecreasedinlastfollow-up [22, 30] . Thismightbeattributabletothefacts,asbelow.First,as showninthestudyofnaturalhistoryofBRVO,without diffusemacularischemia,macularedemaspontaneously resolves,andvisualacuityimprovestosomedegreewithout anytreatmentin6-9mo.Also,unlikeCRVO,inwhich, anatomicobstructionoccursatorjustposteriortolaminar cribrosa,causingdiffuseretinalischemia,BRVOonlyaffects relativelysmallareas.Inthatregard,afterintravitreal bevacizumab,vitreousVEGFleveliswellmaintainedunder physiologiclevel [22] . 
